Chicago Board of Trade (CBOT)

Liffe to clear credit derivatives in Q4

London-based derivatives exchange Liffe will begin clearing contracts linked to the Markit iTraxx indexes of European credit default swaps (CDSs) during the fourth quarter of 2008.

CBOE rights debate could be overcome

A major impediment to the Chicago Board Options Exchange’s (CBOE) planned demutualisation could be overcome by a settlement it presented to its members on June 2.

CME Group in talks to buy Nymex

Chicago-based CME Group is in preliminary discussions aimed at acquiring the New York Mercantile Exchange (Nymex), the two firms announced on January 28.

CME to expand its S&P portfolio

After losing its licensing agreement with Russell Investment Group to the Intercontinental Exchange (ICE), the Chicago Mercantile Exchange (CME) has announced it will expand its Standard & Poor's equity index futures portfolio with an index for small-cap…

ICE takes over Russell Index futures contracts

The Intercontinental Exchange (ICE) has won exclusive rights to derivatives on the Russell series of equity indexes. The deal could give the exchange the edge in the continuing takeover battle over the Chicago Board of Trade.

Jade to launch crude palm oil futures

The Joint Asian Derivatives Exchange (Jade), a Singapore-based electronic commodity derivatives exchange, will launch a crude palm oil (CPO) futures contract on June 6.

CME targets credit derivatives market

The Chicago Mercantile Exchange plans to launch credit derivatives products early next year, with a view to capturing a share of a market that has largely been the preserve of over-the-counter dealers.

CME and CBOT to merge

The Chicago Mercantile Exchange and the Chicago Board of Trade are to merge, forming a new exchange valued at $25 billion.

CBOT to distribute Jade data

The Chicago Board of Trade (CBOT) will start releasing futures data from the Joint Asian Derivatives Exchange (Jade) this week.

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here